121 related articles for article (PubMed ID: 7735476)
1. Megabore capillary gas-liquid chromatographic method with nitrogen-phosphorus selective detection for the assay of haloperidol and reduced haloperidol in serum: results of therapeutic drug-monitoring during acute therapy of eight schizophrenics.
Ulrich S; Meyer FP; Neuhof S; Knorr W
J Chromatogr B Biomed Appl; 1995 Jan; 663(2):289-96. PubMed ID: 7735476
[TBL] [Abstract][Full Text] [Related]
2. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
[TBL] [Abstract][Full Text] [Related]
3. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia.
Ulrich S; Neuhof S; Braun V; Meyer FP
Int Clin Psychopharmacol; 1999 Jul; 14(4):219-28. PubMed ID: 10468314
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
Aravagiri M; Marder SR; Van Putten T; Marshall BD
J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490
[TBL] [Abstract][Full Text] [Related]
5. Plasma reduced haloperidol/haloperidol ratios in schizophrenic patients treated with high dosages of haloperidol.
Chang WH; Shieh YS; Liu HC; Jann MW; Chien CP
Eur Neuropsychopharmacol; 1994 Jun; 4(2):119-26. PubMed ID: 7919941
[TBL] [Abstract][Full Text] [Related]
6. Determination of haloperidol and reduced haloperidol in human serum by liquid chromatography after fluorescence labeling based on the Suzuki coupling reaction.
Kishikawa N; Hamachi C; Imamura Y; Ohba Y; Nakashima K; Tagawa Y; Kuroda N
Anal Bioanal Chem; 2006 Oct; 386(3):719-24. PubMed ID: 16957915
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol and reduced haloperidol serum levels: correlation with psychopathology in acute schizophrenia.
Stevens A; Mahal A; Gaertner HJ
Pharmacopsychiatry; 1992 Sep; 25(5):218-23. PubMed ID: 1409866
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
Ulrich S; Neuhof S; Braun V; Meyer FP
Pharmacopsychiatry; 1998 Sep; 31(5):163-9. PubMed ID: 9832347
[TBL] [Abstract][Full Text] [Related]
9. Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization.
Hoja H; Marquet P; Verneuil B; Lotfi H; Dupuy JL; Pénicaut B; Lachâtre G
J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):275-80. PubMed ID: 9061465
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
11. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables.
Lane HY; Chang WH; Chang YC; Hu OY; Lin HN; Jann MW; Hu WH
Psychiatry Res; 1997 Sep; 72(2):127-32. PubMed ID: 9335203
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia.
Leroux JM; Elia E; Jacquet M; Pommery J; Levron JC; Bouhours P; Erb F; Sechter D
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Mar; 18(2):347-53. PubMed ID: 8208983
[TBL] [Abstract][Full Text] [Related]
14. Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
Browning JL; Harrington CA; Davis CM
J Immunoassay; 1985; 6(1-2):45-66. PubMed ID: 4019788
[TBL] [Abstract][Full Text] [Related]
15. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
[TBL] [Abstract][Full Text] [Related]
16. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients.
Moulin MA; Davy JP; Debruyne D; Andersson JC; Bigot MC; Camsonne R; Poilpré E
Psychopharmacology (Berl); 1982; 76(4):346-50. PubMed ID: 6812109
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatographic determination of reduced haloperidol and haloperidol concentrations in packed red blood cells from humans.
Vatassery GT; Herzan LA; Dysken MW
J Anal Toxicol; 1990; 14(1):25-8. PubMed ID: 2314059
[TBL] [Abstract][Full Text] [Related]
18. Trace analysis of haloperidol and its chiral metabolite in plasma by capillary electrophoresis.
Wu SM; Ko WK; Wu HL; Chen SH
J Chromatogr A; 1999 Jun; 846(1-2):239-43. PubMed ID: 10420615
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection.
Korpi ER; Phelps BH; Granger H; Chang WH; Linnoila M; Meek JL; Wyatt RJ
Clin Chem; 1983 Apr; 29(4):624-8. PubMed ID: 6831688
[TBL] [Abstract][Full Text] [Related]
20. Ketone reductase activity and reduced haloperidol/haloperidol ratios in haloperidol-treated schizophrenic patients.
Huang HF; Jann MW; Tseng YT; Chung MC; Chien CP; Chang WH
Psychiatry Res; 1995 Jul; 57(2):101-8. PubMed ID: 7480377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
